Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors

Part of paid clinical trials in Sioux Falls, South Dakota.

Sponsor
Bristol-Myers Squibb
Study ID
NCT04349267
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Advanced Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BMS-986315 — BIOLOGICAL
    Specified dose on specified days
  • nivolumab — BIOLOGICAL
    Specified dose on specified days
  • cetuximab — BIOLOGICAL
    Specified dose on specified days

Study Details

The purpose of this study is to evaluate BMS-986315 alone and in combination with nivolumab or cetuximab in participants with advanced solid tumors.

Key Dates

Start date
Jul 14, 2020
Status verified
Dec 2025
Primary completion
Aug 22, 2024
Completion
Aug 22, 2024

Study Design

Enrollment
44 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: BMS-986315
  • Experimental: BMS-986315 + nivolumab
  • Experimental: BMS-986315 + cetuximab

Primary Outcome Measure

Number of Participants With Adverse Events and Deaths [ Time Frame: From first dose (Day 1) and 100 days after last dose of study therapy (up to approximately 25 months) ]

Locations (2)

FacilityCityStateZIPSite coordinators
Local Institution - 0028Sioux FallsSouth Dakota57104-
Local Institution - 0001GermantownTennessee38138-

Related coverage on Hipa.ai

Find similar trials in Sioux Falls, SD

By research site
Local Institution - 0028· Sioux Falls, SDLocal Institution - 0001· Germantown, TN

Related Studies